Scinai Immunotherapeutics Ltd. (SCNI) is a biomedical company specialising in the research and development of innovative immunotherapies for the treatment of cancer. Founded with the mission to revolutionise cancer therapy, SCNI has been a pioneer in the discovery and development of novel, targeted immunotherapies that offer a compelling alternative to traditional treatments.
The company operates at the cutting edge of the rapidly growing field of immunotherapy and leverages the most promising scientific advancements to develop next-generation cancer treatments. SCNI's team of experienced biotechnologists, oncologists, and scientists are widely recognised for their expertise in cancer biology and immunology.
SCNI's rich pipeline of investigational drugs includes multiple therapeutic candidates at various stages of clinical development. Their innovative approach to drug development is primarily focused on harnessing the power of the body's immune system to fight cancer. They aim to create treatments that not only attack cancer cells directly but also stimulate immune responses that help the body eliminate cancer cells on its own.
However, what truly sets SCNI apart is its commitment to research. The company has invested heavily in preclinical research, and their scientists are continually exploring new ways to unleash the immune system's power against cancer. They are creating a platform that bridges the gap between research, development, and commercialisation to efficiently bring new therapies to market.
SCNI’s work has led to significant advancements in oncology, dramatically improving patient survival rates and quality of life. While their promising therapeutics have potential to transform cancer treatment, they also represent hope for millions of patients around the world diagnosed with different types and stages of cancer.
SCNI additionally facilitates powerful collaborations within the scientific and medical community. Joining forces with leading research institutions and biotech companies worldwide is integral to its strategy, all in the pursuit of advancing scientific understanding, accelerating the development pipeline and delivering life-enhancing therapies.
Their pursuit of innovation underpins all they do, as they continue to explore the full potential of immunotherapeutics. Although SCNI's primary focus is cancer, its pioneering research in immunotherapy may also hold the promise for the treatment of other diseases.
In conclusion, Scinai Immunotherapeutics Ltd. is not just a pharmaceutical company but a hub of innovation, collaboration and dedication fighting against one of the world’s deadliest diseases – cancer. As it continues to push the boundaries of science and medicine, SCNI stands as a beacon of hope for cancer patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Scinai Immunotherapeutics Ltd. has filed a Form F-3 registration statement with the SEC for the resale of up to 7,587,543 American Depositary Shares (ADSs) by selling shareholders. These ADSs are convertible from various warrants issued on October 13, 2026. Scinai will not receive proceeds from the resale but will gain from warrant exercise prices.
Scinai Immunotherapeutics Ltd. (SCNI) has regained compliance with Nasdaq's $1.00 minimum bid price rule, removing the immediate threat of delisting after maintaining closes above $1.00 for 19 consecutive trading days. This compliance allows management to refocus on advancing its NanoAb immunology programs and expanding CDMO operations. The stock's recent volatility and low valuation metrics, combined with the removed delisting risk, position it as a speculative play for active traders looking for news-driven movements.
Scinai Immunotherapeutics Ltd. (SCNI) stock has risen by 7.76% after regaining full Nasdaq compliance by maintaining a share price above $1.00 for 19 consecutive trading days. This compliance removes the immediate delisting threat, allowing traders to focus on the company's NanoAb immunology programs and its contract development and manufacturing (CDMO) operations. Despite being in an early, high-risk stage with negative returns on assets and equity, the compliance win and ongoing pipeline developments provide clear catalysts for active traders monitoring its volatile performance.
Scinai Immunotherapeutics Ltd. (SCNI) has regained compliance with Nasdaq's $1.00 minimum bid price rule after maintaining closes above $1.00 for 19 consecutive trading days. This removes the immediate delisting threat, shifting focus back to the company's NanoAb immunology programs and growing CDMO operations. Despite its early-stage financials and high volatility, the removal of delisting risk makes SCNI a de-risked yet still speculative opportunity for momentum traders.